Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone hydrochloride versus sufentanil in septic acute lung injury
ChiCTR2400080454Phase 4Not yet recruiting
- Sponsor
- Tianjin Nankai Hospital
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oxycodone in acute lung injury (ALI) and sepsis (2 arms), sponsored by Tianjin Nankai Hospital. Primary endpoints: Change in oxygenation and gas exchange indices and Change in lung injury score after intubation. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
oxycodone
03
Conditions
acute lung injury (ALI)sepsis
Beyond the preview
Go deeper on ChiCTR2400080454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080454.